Novo's Proposed Insulin Drugs Could Pose Risks, FDA Says
U.S. Food and Drug Administration reviewers on Tuesday raised concerns about risks of heart problems and stroke among diabetes patients using Novo Nordisk A/S' proposed insulin treatments Tresiba and Ryzodeg, potentially...To view the full article, register now.
Already a subscriber? Click here to view full article